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ABSTRACT  
Background: Diabetes mellitus (DM) is an important complication of pregnancy 
which may carry adverse effects on both mother and fetus. While insulin is 
effective in controlling high blood glucose levels, otherwise resistant to diet and 
exercise management, several factors hinder its usage. Metformin has been 
found to be a convenient, cheap, effective and safe hypoglycaemic agent in 
some countries. It is possible that metformin will have similar beneficial effects 
among Malaysian pregnant women. 
 
Aim:  The main aim of this study was to determine that metformin is an effective 
treatment for glycaemic control in the gestational diabetes mellitus (GDM) 
population in Malaysia as compared to insulin. It is also to assess the safety of 
these treatments by evaluating the maternal and fetal outcomes in GDM patients 
treated either with metformin or insulin. 
  
Methodology: A prospective, open label, randomized controlled study involving 
99 pregnant women recruited between 12 – 32 weeks gestation, diagnosed with 
GDM. Patients were randomized to be either in the insulin group (n=48) or 
metformin group (n=51). Participants were followed-up throughout their 
pregnancy with a 2-weekly BSP monitoring till date of delivery. Mother and 
perinatal outcomes were followed-up till mother and baby were discharged from 
the ward postnatally. Both laboratory and clinical data were recorded and 
analyzed. 
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Results: 98% and 95% of participants in the metformin and insulin groups 
respectively completed the study. The primary outcomes in comparing the 
differences of capillary blood glucose (BSP) levels between metformin group and 
insulin group shown that there is no significance difference between metformin 
group and insulin group at all different treatment periods. 
 
Maternal weight gains between both groups were no significantly different- at 
8.8kg (±4.27) in metformin group to the 8.8kg (±3.43) insulin group (p > 0.950). 
The rates of maternal hypertension complications did not differ significantly 
between the two groups. Higher reported cases of urinary tract infection (UTI) in 
metformin group as in 30% while only 6.5% in the insulin group (p=0.003).  
 
Average birth weight in the metformin group [3.1kg (±0.26)] is similar to the 
insulin group [3.0kg (±0.48)]. No significance difference in neonatal morbidity; 
hypoglycemia, hyperbilirubinaemia or respiratory disorder, was observed 
between metformin and insulin group. 
 
Conclusion: Efficacy of metformin therapy was similar to insulin in giving good 
optimum glycaemic control in GDM women in Malaysia and carries similar low 
risk in term of maternal and perinatal outcomes. However, more studies with 
larger sample numbers, wider sample population are needed to collaborate these 
findings. 
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ABSTRAK 
Latar Belakang: Kencing manis ketika mengandung adalah suatu penyakit 
yang sangat lazim berlaku dan membawa impak kesan negatif kepada ibu dan 
bayi dalam kandungan. Walaupun insulin merupakan ubat yang sangat efektif 
bagi pengawalan kencing manis, terdapat beberapa perkara yang menghindar 
penggunaannya. Sebaliknya, metformin adalah ubat kencing manis yang 
didapati lebih murah, efektif, pengguna mesra dan selamat dikalangan negara-
negara tertentu. Diharapkan metformin akan memberi kebaikan yang sama 
dalam pengawalan kencing manis dalam golongan ibu-ibu hamil di Malaysia. 
 
Tujuan:  Tujuan utama kajian ini adalah untuk membuktikan bahawa 
metformin adalah efektif dalam pengawalan gula dalam darah yang optimum 
dalam golongan wanita hamil berkencing manis di Malaysia seperti ubat insulin. 
Ia juga bertujuan untuk memastikan keselamatan ubat dengan mengkaji 
komplikasi-komplikasi keatas ibu dan bayi pesakit kencing manis yang menerima 
rawatan metformin atau insulin. 
 
Kaedah:  Ini adalah RCT melibatkan 99 orang wanita hamil yang berpenyakit 
kencing manis, direkrut diantara 12-32 minggu mengandung. Mereka secara 
rawak ditempatkan samaada dalam kumpulan insulin (n=48) atau kumpulan 
metformin (n=51). Ujian gula dalam darah dibuat setiap dua minggu sekali 
sepanjang proses mengandung sehingga tempoh bersalin. Data mengenai 
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bacaan ujian darah, komplikasi-komplikasi yang dihadapi oleh pesakit atau bayi 
dikumpul dan dikaji. 
 
Keputusan: 98% dan 95% wanita dalam kumpulan metformin dan insulin telah 
disusuli sehingga tamat kajian. Keputusan utama telah membuktikan bahawa 
tidak ada perbezaan ketara diantara kumpulan metformin dan insulin dari segi 
pengawalan gula dalam darah (BSP) bagi pesakit berkencing manis ketika 
mengandung. 
 
Keputusan sampingan adalah peningkatan berat badan wanita mengandung 
diantara kedua-dua kumpulan adalah antara 8.8kg (±4.4) dalam kumpulan 
metformin berbanding dengan 8.8kg (±3.43) dalam kumpulan insulin (p>0.950). 
Ini bermakna tidak ada perbezaan diantara kedua-dua kumpulan. 
 
Kes penyakit darah tinggi dan komplikasinya diantara insulin dan metformin 
kumpulan adalah sama. Kes jangkitan infeksi pundi kencing (UTI) lebih tinggi 
dalam kumpulan metformin (30%) berbanding insulin (6.5%) (p<0.003) 
 
Purata berat bayi dalam kumpulan metformin [3.1kg (±0.26)] sama dengan 
kumpulan insulin [3.0kg (±0.48)]. Tidak ada perbezaan dalam kes-kes komplikasi 
keatas bayi seperti gula rendah, jaundice atau masalah pernafasan. 
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Kesimpulan: Rawatan metformin adalah sama dengan rawatan insulin dalam 
memberi kawalan gula dalam darah yang optimum dikalangan wanita menghidap 
kencing manis ketika mengandung di Malaysia. Ia juga membantu mengawal 
komplikasi-komplikasi kencing manis bagi ibu dan bayi sama seperti insulin. 
 
Walaubagaimanapun, adalah disarankan lebih banyak kajian dibuat dengan 
jumlah peserta yang lebih ramai dan melibatkan kawasan kajian yang lebih besar 
bagi menyokong kajian ini.    
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1)  INTRODUCTION 
1.1) OVERVIEW OF THE STUDY 
Gestational diabetes mellitus (GDM) is defined as “glucose intolerance with onset 
or first recognition during pregnancy (Metzger BE and Couston DR, 1998). These 
criteria for the diagnosis were initially established more than 40 years ago and, 
with minor modifications, remain in use today. GDM is a very strong risk factor for 
the development of type 2 diabetes (T2DM) in later life. Published studies have 
shown that after GDM, 35-60% of women develop type 2 diabetes within 10 
years (Metzger BE et al, 2007).  
 
Several theories were proposed to explain why the rates of GDM and T2DM 
were found higher in Asian population:- 
 Genetic studies of GDM and T2DM have demonstrated several shared 
gene loci (Petry C et al, 2010). Ethnic differences in gene loci associated 
with T2DM have been demonstrated between Thai and Caucasian women 
supporting the above theory. 
 The number of low birth weight babies is concentrated in two regions of 
the developing world: Asia and Africa. 72% of low birth weight infants in 
developing countries are born in Asia. 22% are born in Africa. There are 
more than 1 million infants born with low birth weight in China and nearly 8 
million in India (UNICEF, 2004). In 1992, Hales and Barker proposed the 
model of the “thrifty phenotype,” suggesting that intrauterine growth 
retardation (IUGR) and low birth weight can lead to insulin resistance and 
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decreased beta cell mass, thus predisposing to T2DM later in life (Hales 
and Barker, 1992).  
 
The prevalence of diabetes in Peninsular Malaysia as reported in the 1st National 
Health and Morbidity Survey in 1986 was at 6.3%. National Obstetric Registry 
(2009) data shows there were 136856 deliveries in the 14 state hospitals in 
Malaysia. The incidence of diabetes in pregnancy is 9.9% in which majority is 
GDM 11,848 (8.6%) and 1009 (0.74%) is preexisting diabetes mellitus (DM). A 
local study in Negeri Sembilan has reported a high prevalence for GDM, which is 
18.3% (Idris N et al, 2009). Therefore, it is prudent that GDM is diagnosed and 
appropriate treatment and monitoring instituted.  
 
During pregnancy, an increase in insulin resistance occurs due to the effect of 
pregnancy hormones. Euglycaemia is achieved by compensating increase insulin 
secretion. As the increase in insulin resistance is greatest in 3rd trimester, 
screening of GDM is recommended around 24-28 weeks. In Malaysia, we 
advocate high risk pregnancy screening. Patients were considered to be risk-
factor positive if any of the following is present as per recommended by Malaysia 
Clinical Practice guidelines (CPG) May 2009. 
  
o age 25 years and above  
o previous macrosomic baby with birth weight 4.0kg or more  
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o previous unexplained still birth  
o previous baby with congenital abnormally  
o recurrent miscarriages (3 or more)  
o previous pregnancy with gestational diabetes mellitus  
o history of DM in first degree relatives  
o Body mass index (BMI) >27kg/meter square  
 
In Hospital Tuanku Jaafar Seremban, oral Glucose Tolerance Test (OGTT) was 
done for these groups of people as per recommended by Malaysia CPG - 
Management of T2DM Third Edition (2004) using the value of ≥5.6mmol/L for 0-
hour and ≥7.8mmol/L for 2-hour blood glucose level. In this study, the targets 
capillary fasting glucose < 5.3mmol/L and/or 2-hour postprandial glucose of 
<6.7mmol/L: as per recommended by The Fifth International Workshop-
Conference on Gestational Diabetes (2007) were used.   
 
Overt DM during pregnancy is associated with significantly increased risks of 
complications to the pregnancy, adverse perinatal outcomes and a long term risk 
of diabetes in both mother and offspring as demonstrated in the HAPO study 
(Coustan DR, 2004, Dabelea D et al, 2000). First-line therapy is dietary 
modification and moderate exercise. However pharmacotherapy is indicated if 
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maternal hyperglycaemia remains persistence and insulin has traditionally been 
the gold standard drug of choice.   
 
Subcutaneous insulin therapy has been the mainstay treatment of women with 
gestational diabetes not controlled by diet modification and has been shown to 
improve perinatal outcomes (Crowther CA et al, 2005). However, women who 
begin insulin therapy require intense education and instruction to ensure the safe 
administration of insulin. Use of insulin is also associated with the risk of 
hypoglycaemia and weight gain. Insulin treatment is costlier and the 
administration is difficult and inconvenient. 
 
The use of safe and effective oral agents may offer advantages over insulin. 
They are easier to administer, non-invasive and therefore user-friendly. Oral 
metformin is a logical option for women with GDM. Metformin was first described 
in scientific literature in 1922, but only made available worldwide in Britain 
(1958), Canada (1972) and USA (1994). Historically, some of the earliest reports 
of the use of metformin during pregnancy have come from South Africa, where it 
has been used since the late 1970s for women with both T2DM and GDM 
(Coetzee EJ and Jackson WPU 1979, 1980, 1984, 1985).  
In Hospital Tuanku Jaafar, metformin has been used in combine with insulin in 
patient with GDM and T2DM with extreme high dose of insulin per day. It 
improves insulin sensitivity, probably by activating AMP kinase, thus enhances 
 20 
peripheral glucose uptakes, improves insulin binding to the insulin receptor and 
reduces absorption of glucose in gastrointestinal tract.  
 
 Since then, multiple small studies have been done to explore the effectiveness 
of metformin in improving fertility in patient with polycystic ovarian syndrome 
(PCOS) such as studies done by (Tang T in 2010 and Palomba S in 2009)  that 
look at the improvement of early pregnancy and reduction of 1st trimester 
miscarriage in PCOS patient on metformin through out pregnancy. No obvious 
adverse effect or cases of tetratogenicity were reported in these studies.  
 
Since then, many other studies have been done on metformin for the treatment 
of GDM (Goh JE 2011, Rai L 2009, Balani J 2009). A recent systematic review 
and meta analysis (Jaya SD et al, 2010) involving six studies comprising 1388 
subjects were analyzed. It has shown no significant differences were found in 
maternal fasting (weighted mean difference [WMD], 1.31; 95% confidence 
interval [CI], 0.81–3.43) or postprandial (WMD, 0.80; 95% CI, –3.26 to 4.87) 
glycaemic control. Use of OHA was not associated with risk of neonatal 
hypoglycaemia (odds ratio [OR], 1.59; 95% CI, 0.70–3.62), increased birth weight 
(WMD, 56.11; 95% CI, –42.62 to 154.84), incidence of caesarean section (OR, 
0.91; 95% CI, –0.68 to 1.22), or incidence of large-for-gestational-age babies 
(OR, 1.01; 95% CI, 0.61–1.68). Other outcomes in which no significant 
differences were found between treatments were admission to neonatal intensive 
care units, neonatal respiratory distress and birth injuries, and incidence of small-
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for-gestational-age babies, preterm births, intrauterine foetal death, congenital 
abnormalities and maternal hypoglycaemia. The review concludes that OHA are 
credible and safe alternatives to insulin for the first-line treatment of GDM. In 
selected cases, these agents may be used as adjunctive treatments to insulin in 
the management of gestational diabetes. 
 
Metformin used in pregnancy remains controversial. To our knowledge, only 
small, randomized trials addressing this question have been reported to date 
(Jaya SD 2010, Rowan JA 2008, Glueck CJ 2004, Hague WM 2003). Reported 
outcomes of its use during pregnancy have been favourable and promising. 
However, more randomized trials studies are recommended to support these 
promising outcomes, thus the reason of this study. Also previous studies have 
not been done in Asian community. By doing this study, we will be able to 
provide the Asian population data to support the safety and effectiveness of the 
drug in treatment of GDM in pregnancy. This will hopefully allows future pregnant 
mother with GDM will have another option treatment that is practical, 
convenience and safe. 
  
1.2) NULL HYPOTHESIS 
 Glycaemic control will be equally control with metformin therapy as with 
insulin therapy in GDM patient in Malaysia 
 Maternal outcome and perinatal outcome complication is similar in 
metformin therapy as with insulin therapy 
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1.3) JUSTIFICATION OF THE STUDY 
Several studies have been done in countries like United States of America 
(USA), Australia, Canada and India have shown metformin as an effective 
treatment of GDM as to insulin. However, there is no published data on the use 
of metformin in pregnancy for glycaemic control in Malaysia. Thus, to collect local 
data regarding the perinatal and maternal outcome of GDM on metformin 
treatment in compare to insulin treatment cannot be overemphasized. Hopefully 
in the future, mother with GDM will have the options in the treatment of GDM that 
is more convenience, easier, simple and practical. 
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2)  LITERATURE REVIEW 
2.1 )  DIABETES MELLITUS (DM)   
The World Health Organization (WHO) defines diabetes mellitus as a metabolic 
disorder of multiple aetiology characterized by, chronic hyperglycaemia with 
disturbance of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, insulin action, or both (WHO, 1999). This classification was 
used in this study. 
 
The American Diabetes Association (ADA) categorized DM into four clinical 
classes:  
Type 1 diabetes (results from β-cell destruction, usually leading to absolute 
insulin deficiency)  
 Type 2 diabetes (results from a progressive insulin secretary defect on the 
background of insulin resistance)  
 Other specific types of diabetes due to other causes, e.g., genetic defects 
in β-cell function, genetic defects in insulin action, diseases of the exocrine 
pancreas (such as cystic fibrosis), and drug- or chemical-induced (such as 
in the treatment of HIV/AIDS or after organ transplantation)  
 GDM (diabetes diagnosed during pregnancy that is not clearly overt 
diabetes) (Diabetes Care, 2012)  
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Another method for classifying diabetes in pregnancy is the White classification. 
There are two main groups; GDM (class A) and pre-gestational diabetes (classes 
B-T). In this classification, the class A diabetes is further sub-divided into two as 
follows: 
  Class A1: gestational diabetes; diet-controlled  
  Class A2: gestational diabetes; medication-controlled  
 
Pre-gestational diabetes, or classes B to T is sub-classified as follows: 
 Class B: onset at age 20 or older or with duration of less than 10 years  
 Class C: onset at age 10-19 or duration of 10–19 years  
 Class D: onset before age 10 or duration greater than 20 years  
 Class E: overt diabetes mellitus with calcified pelvic vessels  
 Class F: diabetic nephropathy  
 Class R: proliferative retinopathy  
 Class RF: retinopathy and nephropathy  
 Class H: ischemic heart disease  
 Class T: prior kidney transplant  
 
2.2)  GESTATIONAL DIABETES MELLITUS (GDM)  
GDM is defined as carbohydrate intolerance that begins or is first recognized 
during pregnancy (WHO, 1999). It is a well-known complication of pregnancy but 
its prevalence varies greatly due to differences in screening programmes and 
diagnostic criteria. GDM complicates about 5% of pregnancies with long-term risk 
